1
|
Li X, Ye C, Zhang W, Jia M, Wang G. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia. CNS Drugs 2024; 38:55-65. [PMID: 38190077 PMCID: PMC10810987 DOI: 10.1007/s40263-023-01056-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/20/2023] [Indexed: 01/09/2024]
Abstract
BACKGROUND AND OBJECTIVES Identifying key factors for a successful transition from once-monthly paliperidone palmitate (PP1M) to three-monthly paliperidone palmitate (PP3M) is crucial for improving treatment outcomes, enhancing patient adherence, and reducing relapse risk in patients with schizophrenia. Providing region-specific insights for evidence-based clinical decisions can aid clinicians in optimizing transition strategies for Chinese patients with schizophrenia. Therefore, the objective of this post hoc analysis of a double-blind parallel-group multicenter phase 3 study (NCT01515423) was to identify factors related to the disease stabilization that may allow for a successful transition from PP1M to PP3M in the treatment of Chinese patients with schizophrenia. METHODS Adults (18-70 years) diagnosed with schizophrenia using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition text revision, for over 1 year and with a baseline Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120 were entered into an open-label (OL) phase receiving PP1M for 17 weeks. After the 17-week OL phase, patients who met the criteria necessary for stabilization were randomized (1:1) to PP1M (fixed-dose, 50, 75, 100, or 150 mg eq.) or PP3M (fixed-dose, 175, 263, 350, or 525 mg eq.) in a 48-week double-blind phase. Stabilization was defined as a PANSS total score < 70, PANSS item (P1, P2, P3, P6, P7, G8, G14) scores ≤ 4, and a reduction in Clinical Global Impression Severity (CGI-S) score of ≥ 1 from OL baseline. This post hoc analysis evaluated changes and trends in symptom severity using PANSS, changes in mental states using CGI-S, and changes in personal and social functioning using Personal and Social Performance (PSP) scores from baseline to the endpoint of the OL phase in patients who either met or did not meet the stabilization criteria (stabilized versus non-stabilized group). Comparison of changes and trends in the clinical scores between the stabilized group and non-stabilized group were conducted using linear mixed model and Mann-Kendall trend analysis, respectively. Univariate and multivariate logistic regression analyses were conducted to explore factors associated with stabilization status for transition. RESULTS Of 296 patients enrolled, 210 achieved disease stabilization (106 patients and 104 patients were randomized to PP1M and PP3M, respectively). Significant downward trends in the PANSS and CGI-S scores were detected in the stabilized patients (n = 210, ZPANSS = -2.21, p = 0.028; ZCGI-S = -2.21, p = 0.028) but not in the non-stabilized patients (n = 86). No significant trends in the PSP scores were observed in either group. The factors significantly associated with disease stabilization were the CGI-S score at baseline [odds ratio (OR) = 0.22, 95% confidence interval (CI): 0.09, 0.5), reduction of the PANSS score at week 13 (OR = 1.11, 95% CI: 1.06, 1.17), and reduction of CGI-S score at week 13 (OR = 2.27, 95% CI: 1.03, 5.02). CONCLUSION A lower CGI-S total score at baseline and greater reductions in PANSS and CGI-S scores at week 13 were associated with patients achieving disease stabilization, that may allow for a successful transition. Evidence from this study indicates that better disease condition at baseline, early functional improvement and symptomatic relief were the key factors associated with disease stabilization. The findings may guide clinicians to identify suitable patients for transition from PP1M to PP3M and further optimize the use of PP3M in China. CLINICAL TRIALS REGISTRATION EudraCT number: 2011-004889-15 and ClinicalTrials.gov (identifier: NCT01515423) for the original double-blind randomized study.
Collapse
Affiliation(s)
- Xin Li
- Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China
| | - Chong Ye
- Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China
| | - Wanyi Zhang
- Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China
| | - Miaomiao Jia
- Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China
| | - Gang Wang
- The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Xicheng District, 5 Ankang Hutong, Beijing, 100088, China.
| |
Collapse
|
2
|
Ma N, Zhang L, Zhang W, He Y, Ye C, Li X. Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. Neuropsychiatr Dis Treat 2023; 19:1987-2006. [PMID: 37745189 PMCID: PMC10516218 DOI: 10.2147/ndt.s413371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 09/07/2023] [Indexed: 09/26/2023] Open
Abstract
Evidence of comparative benefits of long-acting injectable (LAI) antipsychotics in Asian patients with schizophrenia has been inconsistent. This scoping review aimed to synthesize the current evidence in the past ten years and provide an overview of efficacy, safety, treatment adherence, patient attitudes, and healthcare resource utilization of LAI in this population. A systematic search was conducted with a pre-defined search strategy in six electronic databases including Chinese National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Embase, CINAHL, and PsycArticles. A total of 46 studies were included, including 15 cohort studies, 13 single-arm trials, 10 randomized controlled trials, four mirror-image studies, three cross-sectional studies, and one controlled clinical trial. Paliperidone palmitate once-monthly injection (27/46) and risperidone LAI (14/46) were the most frequently investigated LAIs. Compared with oral antipsychotic medications (OAMs), LAIs demonstrated a lower rate of relapse/hospitalization and comparable improvement in efficacy. Adverse events (AEs) were similar between LAIs and OAMs, although types and incidence varied. Significant reduction in the length of hospitalization and number of outpatient visits/inpatient admission was observed after initiation of LAIs. These findings suggest that LAI demonstrated comparable efficacy and safety among Asian populations with schizophrenia in comparison to OAMs. Better adherence and lower relapse were observed in patients receiving LAIs from published evidence. Future research is warranted to better understand the comprehensive performance of LAI in specific population or context.
Collapse
Affiliation(s)
- Ning Ma
- Peking University Sixth Hospital, Beijing, People’s Republic of China
- Peking University Institute of Mental Health, Beijing, People’s Republic of China
- NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of China
| | - Lei Zhang
- Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| | - Wufang Zhang
- Peking University Sixth Hospital, Beijing, People’s Republic of China
- Peking University Institute of Mental Health, Beijing, People’s Republic of China
- NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of China
| | - Yingying He
- Peking University Sixth Hospital, Beijing, People’s Republic of China
- Peking University Institute of Mental Health, Beijing, People’s Republic of China
- NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of China
| | - Chong Ye
- Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| | - Xin Li
- Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| |
Collapse
|
3
|
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat 2019; 15:1365-1379. [PMID: 31190840 PMCID: PMC6535080 DOI: 10.2147/ndt.s197225] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Accepted: 04/02/2019] [Indexed: 12/11/2022] Open
Abstract
Antipsychotics are the mainstay in schizophrenia management, and long-acting injectable (LAI) antipsychotics contribute to the successful maintenance of treatment by improving non-adherence and preventing relapses. Paliperidone palmitate 3-monthly (PP3M) formulation is the only available LAI antipsychotic that offers an extended 3-month window of stable plasma drug concentration, enabling only four injections per year. This paper summarizes clinically relevant endpoints from available evidence for PP3M to bridge translational research gaps and provide measurable outcomes that can be interpreted in clinical practice. Low number-needed-to-treat (NNT) for relapse prevention (NNT [95% CI] 6-month estimate: 4.8 [3.2; 10.0]; 12-month estimate: 3.4 [2.2; 7.0]), and high number-needed-to-harm (NNH [95% CI] akathisia, 27.1 [12.3; -667.1]; tremor, 80.0 [22.5; 67.3]; dyskinesia, -132.6 [44.5; -23.2]; parkinsonism, 160.0 [28.9; -49.8]) quantify the relative benefits and low propensity for adverse events with PP3M. Symptom remission and reductions in positive and negative symptoms indicate treatment stability. Additionally, meaningful functional remission, reduced dosing frequency, and freedom from daily negotiations favorably impact patient preference and attenuate burdensome aspects of caregiving, representing important healthcare determinants that enhance prospects of treatment continuity in schizophrenia. This information can potentially improve clinicians' judgment of treatment choices, clinical response, and patient selection in routine care. Taken together, PP3M is a valuable antipsychotic treatment option, meriting consideration for a broader role in the long-term management of schizophrenia; its utility should not be limited to patients with poor adherence or when oral antipsychotics have failed.
Collapse
Affiliation(s)
- Maju Mathews
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Srihari Gopal
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Isaac Nuamah
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Ludger Hargarter
- Department of Neuroscience, Janssen-Cilag EMEA, Neuss, Deutschland
| | - Adam J Savitz
- Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA
| | - Edward Kim
- Janssen Scientific Affairs, LLC, Hopewell, NJ, USA
| | - Wilson Tan
- Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
| | - Bernardo Soares
- Neuroscience Medical Affairs, Janssen-Cilag, High Wycombe, Buckinghamshire, UK
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, NY, USA
- Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, East Garden City, NY, USA
- Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
| |
Collapse
|
4
|
Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat 2019; 15:1685-1694. [PMID: 31303756 PMCID: PMC6603286 DOI: 10.2147/ndt.s191803] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Accepted: 04/02/2019] [Indexed: 11/23/2022] Open
Abstract
Background: The subgroup analysis of a primary study (NCT01051531) evaluated the effect of long-term paliperidone palmitate once-monthly (PP1M) therapy in Chinese patients with recent-onset schizophrenia responding unsatisfactorily to previous oral antipsychotics. Patients and methods: This 18-month, open-label study consisted of 3 phases - screening (7 days), treatment (18 months) and end-of-study/withdrawal visit. All enrolled patients (18-50 years) received PP1M: 150 mg eq. (day 1), 100 mg eq. (day 8) followed by a once-monthly flexible dose (50, 75, 100 or 150 mg eq.). Efficacy and safety were assessed. Results: Among the 118 enrolled Chinese patients, 68 completed the treatment (mean age: 25.6 years; male: 54.7%). A clinically meaningful change from baseline to day 548 was observed in Positive and Negative Syndrome scale (primary endpoint, mean [SD]: -15.3 [20.76]), Personal and Social Performance scale (15.9 [19.65]), Clinician Global Impression-schizophrenia score (-1.2 [1.54]) and Medication Satisfaction Questionnaire score (0.9 [1.73]). Commonly reported treatment-emergent adverse events (TEAEs) included insomnia (13.9%), injection-site pain (13.9%), upper respiratory tract infection (13.0%), restlessness (13.0%) and akathisia (13.0%). Serious TEAEs were reported in 9.3% patients with schizophrenia being most common (6.5%) and one death (suicide) was observed. Conclusion: Efficacy of PP1M corroborate findings from earlier studies and no new safety concerns emerged in this Chinese subgroup of patients with schizophrenia.
Collapse
Affiliation(s)
- Tianmei Si
- National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People's Republic of China.,Peking University Institute of Mental Health/The Sixth Hospital, Beijing, People's Republic of China
| | - Jianmin Zhuo
- Janssen (China) Research & Development Center, Johnson & Johnson (China) Investment Ltd., Shanghai, People's Republic of China
| | - Yu Feng
- Department of Neuroscience, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
| | - Huafei Lu
- Medical Affairs, Xi'an Janssen Pharmaceuticals, Beijing, People's Republic of China
| | - Di Hong
- Medical Affairs, Xi'an Janssen Pharmaceuticals, Beijing, People's Republic of China
| | - Lili Zhang
- Medical Affairs, Xi'an Janssen Pharmaceuticals, Beijing, People's Republic of China
| |
Collapse
|
5
|
Si T, Li N, Lu H, Cai S, Zhuo J, Correll CU, Zhang L, Feng Y. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. J Psychopharmacol 2018; 32:691-701. [PMID: 29764266 PMCID: PMC6024380 DOI: 10.1177/0269881118772449] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. AIM To investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia. METHODS This was a post-hoc analysis from an open-label, single-arm study of stable patients (Positive and Negative Syndrome Scale total score <70; n=367) receiving paliperidone palmitate one-month formulation at the end of an acute 13-week treatment phase, who entered a naturalistic one-year follow-up period, either continuing with flexibly dosed paliperidone palmitate one-month formulation (75-150 mg eq.) or switching to another antipsychotic(s). RESULTS There were 362/367 patients (age=31.4±10.75 years) included in the analysis of time to first relapse (primary outcome) and 327/362 patients (39/327, poor antipsychotic adherence (<80%)) willing to receive antipsychotics were included in the exposure/adherence analysis. Overall, 84.6% (95% confidence interval=79.2-88.7) patients remained relapse-free. Poor adherence during follow-up (hazard ratio=2.97, 95% confidence interval=1.48-5.98, p=0.002) and frequent hospitalizations in the previous year (hazard ratio=1.29, 95% confidence interval=1.02-1.62, p=0.03) were associated with a significant risk of shorter time to first relapse in the univariate analysis. In patients with poor adherence, 'no use' (hazard ratio=13.13, 95% confidence interval=1.33-129.96, p=0.03) and 'interrupted use' (hazard ratio=11.04, 95% confidence interval=1.03-118.60, p=0.047) of paliperidone palmitate one-month formulation (vs continued use) showed a significantly higher risk of relapse; this was not observed in patients with good (≥80%) antipsychotic adherence. No new safety concerns were identified. CONCLUSION Continued use of paliperidone palmitate one-month formulation/long-acting injectable antipsychotic was effective in preventing schizophrenia relapses, especially in patients with suboptimal antipsychotic adherence.
Collapse
Affiliation(s)
- Tianmei Si
- National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health, Beijing, People’s Republic of China,Institute of Mental Health/the Sixth Hospital, Peking University, Beijing, People’s Republic of China
| | - Nan Li
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People’s Republic of China
| | - Huafei Lu
- Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| | - Shangli Cai
- Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| | - Jianmin Zhuo
- Johnson & Johnson (China) Investment Ltd, Shanghai, People’s Republic of China
| | - Christoph U Correll
- Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, USA,Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA
| | - Lili Zhang
- Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China
| | - Yu Feng
- Janssen Pharmaceutical Companies, Johnson and Johnson, Singapore,Yu Feng, Janssen Pharmaceutical Companies of Johnson and Johnson, Ascent, 2 Science Park Drive, Singapore Science Park 1, Singapore 118222, Singapore.
| |
Collapse
|
6
|
Li N, Feng Y, Lu H, Cai SL, Zhuo J, Si T, Zhang L. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat 2018; 14:825-837. [PMID: 29606876 PMCID: PMC5868613 DOI: 10.2147/ndt.s158353] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and functional remission in patients with schizophrenia. This post hoc analysis aimed to identify factors associated with improved clinical outcomes in patients switching to PP1M (75-150 mg eq.). METHODS The improved patient outcomes were observed as Positive and Negative Symptom Scale (PANSS, symptoms) score <70:66.7% (407/610), Personal and Social Performance (PSP, function) score >70:34.3% (199/581), and Involvement Evaluation Questionnaire (IEQ, caregiver burden) reduction ≥6:50.2% (270/538). Independent variables including demographics, disease duration, employment status, and clinical scores were screened individually using a univariate analysis and subsequently, variables (cutoff p<0.15) were analyzed using a multivariate regression analysis for association with better clinical outcomes at week 13. RESULTS The factors significantly associated with favorable clinical outcomes were reduction in PANSS at week 5 (odds ratio [OR]=1.14, 95% CI=1.11-1.17) with symptom reduction; baseline PSP total score (OR=1.07, 95% CI=1.05-1.10), PSP change at week 5 (OR=1.07, 95% CI=1.05-1.10), PANSS reduction at week 5 (OR=1.06, 95% CI=1.03-1.08) with functional improvement, reduction in PANSS at week 5 (OR=1.02, 95% CI=1.01-1.03), and total IEQ score at baseline (OR=1.09, 95% CI=1.07-1.11) with caregiver burden reduction. CONCLUSION Thus, symptom and functional improvements with caregiver burden reduction were observed in patients, and PANSS reduction at week 5 was commonly associated with favorable outcomes.
Collapse
Affiliation(s)
- Nan Li
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People's Republic of China
| | - Yu Feng
- Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
| | - Huafei Lu
- Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People's Republic of China
| | - Shang Li Cai
- Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People's Republic of China
| | - Jianmin Zhuo
- Department of Statistics, Janssen China Research and Development, Shanghai, People's Republic of China
| | - Tianmei Si
- National Clinical Research Center for Mental Disorders and The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People's Republic of China.,Peking University Institute of Mental Health (The Sixth Hospital), Beijing, People's Republic of China
| | - Lili Zhang
- Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People's Republic of China
| |
Collapse
|
7
|
Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia. Adv Ther 2017; 34:2503-2517. [PMID: 29101715 PMCID: PMC5702374 DOI: 10.1007/s12325-017-0638-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Indexed: 12/03/2022]
Abstract
Introduction Post hoc analyses (two single-arm studies) were conducted to determine the impact of once-monthly injection of paliperidone palmitate on functioning in adult patients with schizophrenia in the Asia–Pacific region. Methods Study 1 enrolled hospitalized patients with acute exacerbation of schizophrenia, and study 2 enrolled patients with recently diagnosed schizophrenia unsatisfactorily treated with oral antipsychotics. Patients received paliperidone palmitate, 150 mg eq. on day 1, 100 mg eq. on day 8, then once monthly (50–150 mg eq.) (study 1, days 36 and 64; study 2, 18 months). Functional status was evaluated by Personal and Social Performance score in both studies and employment only in study 2. Results In study 1, 54 of 184 patients (29.4%) with an unfavorable level of functioning at the baseline improved to a favorable level (Personal and Social Performance score greater than 70) at day 92. This improvement was significantly greater among patients with recently diagnosed schizophrenia (5 years or less) compared with patients with chronic schizophrenia (more than 5 years): 40% versus 22% (p < 0.0001). Improvements were observed in all four domains (socially useful activities, personal and social relationships, self-care, disturbing/aggressive behavior). In study 2, significant (p < 0.0001) improvement in functioning was observed at all visits, beginning at week 5. Almost half (48.7%, 247/507) of patients showed clinically meaningful improvement in functioning (i.e., 10 point or greater increase in Personal and Social Performance score) at month 18. The proportion of patients fully/partially employed was greater at all postbaseline visits (134 of 280, 47.9%, at month 18) as compared with the baseline. Conclusion Functioning, including employment, was improved after short-term, once-monthly paliperidone palmitate injection, and was sustained to 18 months in Asia–Pacific patients with schizophrenia. Funding Janssen-Cilag Asia–Pacific Medical Affairs.
Collapse
|
8
|
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon JS, Chen JJ. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatr Dis Treat 2017; 13:2193-2207. [PMID: 28860777 PMCID: PMC5566420 DOI: 10.2147/ndt.s134287] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE To demonstrate the efficacy and safety of paliperidone palmitate three-monthly (PP3M) formulation in an East Asian population with schizophrenia by subgroup analysis of a double-blind (DB), multicenter, noninferiority study. PATIENTS AND METHODS Of 1,429 patients who entered the open-label (OL) phase, 510 were East Asian (China: 296 [58%], Japan: 175 [34%], South Korea: 19 [4%] and Taiwan: 20 [4%]). In the 17-week OL phase, patients received paliperidone palmitate once-monthly (PP1M) formulation on day 1 (150 mg eq.), day 8 (100 mg eq.) and once-monthly thereafter (50-150 mg eq., flexible). Following the OL phase, patients (n=344 East Asian) entered DB phase and were randomized (1:1) to PP1M (n=174) or PP3M (n=170). Primary efficacy endpoint was the percentage of patients who remained relapse free at the end of the 48-week DB phase, using Kaplan-Meier cumulative survival estimate. Secondary efficacy endpoints included change from DB baseline to endpoint in Positive and Negative Syndrome Scale, Clinical Global Impression Severity, Personal and Social Performance scores and symptomatic remission. Additional assessments included caregiver burden and safety. RESULTS A total of 285/344 (83%) randomized East Asian patients completed the DB phase. The percentage of patients who had a relapse event was similar on comparing PP3M (17 [10.2%]) to PP1M (20 [11.8%]), and also for Japan (PP3M: 9 [17.6%], PP1M: 13 [23.2%]) and China (PP3M: 6 [5.9%], PP1M: 7 [6.9%]). Mean change from baseline in secondary efficacy parameters was similar to the global population, regardless of treatment. Symptomatic remission was attained by 50% of the treated patients. Caregiver burden was significantly reduced (P<0.001) following treatment with PP3M/PP1M. Frequency of treatment-emergent adverse events in PP3M group during DB phase was greater in the East Asian subgroup (81%) than the global population (68%) and was higher in Japan (92%) than China (75%). CONCLUSION Results suggest that PP3M is efficacious in the East Asian subgroup. Although treatment-emergent adverse events were slightly higher in the East Asian subgroup versus the global population, no new safety signals were identified.
Collapse
Affiliation(s)
| | - Haiyan Xu
- Department of Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA
| | | | - Isaac Nuamah
- Department of Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA
| | - Paulien Ravenstijn
- Department of Clinical Pharmacology, Janssen Research & Development, Beerse, Belgium
| | | | - Maju Mathews
- Global Medical Affairs, Neurosciences, Janssen Research & Development, NY, USA
| | - Yu Feng
- Medical Affairs, Neurosciences, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
| | - Lu Yu
- Department of Clinical Development, Janssen Research & Development, Beijing, China
| | - Masayoshi Takahashi
- Department of Central Nervous System, Janssen Pharmaceutical KK, Tokyo, Japan
| | - Dennis Liu
- Playford Community Team, Northern Adelaide Local Health Network, Adelaide, SA, Australia
| | - Gang Wang
- National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Affiliated Capital University of Medical Science, Beijing, China
| | - Jin-Sang Yoon
- Department of Psychiatry, Chonnam National University Hospital, Gwangju, South Korea
| | - Jiahn-Jyh Chen
- Department of Geriatric Psychiatry, Taoyuan Mental Hospital, Taoyuan, Taiwan
| |
Collapse
|
9
|
Zhao J, Li L, Shi J, Li Y, Xu X, Li K, Zhang L, Cai S, Feng Y, Zhuo J, Liu W, Lu H. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatr Dis Treat 2017; 13:2045-2056. [PMID: 28814873 PMCID: PMC5546821 DOI: 10.2147/ndt.s131224] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
RATIONALE Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese patients is of interest. OBJECTIVE The aim of this study is to evaluate the long-term safety and efficacy of PP1M treatment in Chinese patients with schizophrenia. METHODS In this 25-week, open-label, Phase IV study, patients (18-65 years) diagnosed with schizophrenia and having a baseline Positive and Negative Syndrome Scale (PANSS) total score of 60-120 (inclusive) were enrolled. All patients received injections of PP1M 150 mg eq. (day 1) and 100 mg eq. (day 8), followed by a flexible once-monthly maintenance dosing (75, 100, or 150 mg eq.). RESULTS Of the 353 patients, 234 (66.3%) completed the study treatment (mean age, 31.1 years; 52.7% men). The PANSS total score (primary end point) improved significantly over the 6-month treatment period (mean [standard deviation] change from baseline to end of treatment, -27.2 [18.30]; P<0.0001). The Clinical Global Impressions-Severity and Personal and Social Performance scores (secondary end points) also improved significantly (P<0.0001). At 6 months, PP1M had a positive impact on medication satisfaction, adherence, and increased preference for LAIs. Treatment-emergent adverse events (TEAEs) were reported by 181 (51.3%) patients (TEAEs ≥5%: extrapyramidal disorder [15.3%], akathisia [10.5%], blood prolactin increase [8.8%], insomnia [5.4%]). A total of 8 deaths were reported, including 4 completed suicides. CONCLUSION Long-term treatment with PP1M was efficacious, and no new safety concerns were identified in Chinese patients with schizophrenia. Overall, the results were comparable with observations from previous studies.
Collapse
Affiliation(s)
- Jingping Zhao
- Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University
| | - Lehua Li
- Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University
| | - Jianguo Shi
- Department of Psychiatry, Mental Health Center of Xi'an City
| | - Yi Li
- Department of Psychiatry, Mental Health Center of Wuhan City
| | - Xiufeng Xu
- Department of Psychiatry, First Affiliated Hospital of Kunming Medical University
| | - Keqing Li
- Department of Psychiatry, The Sixth People's Hospital of Hebei Province
| | - Lili Zhang
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| | - Shangli Cai
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| | - Yu Feng
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| | - Jianmin Zhuo
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| | - Weihong Liu
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| | - Huafei Lu
- Department of Medical Affairs, Xi'an Janssen Pharmaceutical Ltd., Beijing, People's Republic of China
| |
Collapse
|
10
|
Di Lorenzo R, Cameli M, Bolondi M, Landi G, Moretti V, Piemonte C, Pollutri G. Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study. PSYCHOPHARMACOLOGY BULLETIN 2016; 46:36-53. [PMID: 27738372 PMCID: PMC5044485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVES To evaluate paliperidone palmitate (PP) effectiveness, safety and adherence to treatment. METHODS We collected data of all patients (n = 50) affected by Schizophrenia Disorders, treated with PP for a 3 month minimum period in the outpatient setting of Mental Health Department in Modena, from 01/01/2014 to 31/01/2015. We evaluated reasons and modality for PP implementation, improvement in symptom and functioning scales, adverse effects, discontinuations and relapses. We statistically correlated socio-demographic and clinical variables of our sample with PP therapeutic variables. RESULTS We registered an improvement in all scales, with a superior percentage in PANSS positive subscale. The mean PP dose in some patients was lower than official indications, although our sample was clinically severe. Illness relapses affected 60% and dropout 18% of patients. PP was well tolerated and in just a few cases adverse events required treatment interruption. The risk factors for discontinuation were represented by "lack of therapeutic compliance" (HR = 4.11, p < 0.0001) and "inefficacy" (HR = 1.67, p < 0.0001). CONCLUSIONS With limitations of observational design, this research highlights that PP was well tolerated and effective in improving both psychotic symptoms and functioning, but moderately effective in preventing relapse, probably due to clinical severity of our patients associated with extremely cautious and flexible PP prescriptions.
Collapse
Affiliation(s)
- Rosaria Di Lorenzo
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Michela Cameli
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Marisa Bolondi
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Giulia Landi
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Valentina Moretti
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Chiara Piemonte
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| | - Gabriella Pollutri
- Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy
| |
Collapse
|